Currently, diagnosis of influenza is performed either through either polymerase chain reaction (PCR) or through rapid antigen detection assays. The rapid antigen detection assays currently available are highly specific but not very sensitive, and lack the ability to show if the strain of influenza detected is susceptible to antiviral agents, such as Tamiflu and Relenza. The ability to rapidly determine if a patient has an infectious disease and what type of treatment the infection will respond to, would significantly reduce the treatment decision time, shorten the impact of symptoms, and minimize transfer to others. In this study, a point-of-care style µPAD (microfluidic paper-based diagnostic) for influenza has been developed with the ability to determine antiviral susceptibility of the strain for treatment decision. The assay exploits the enzymatic activity of surface proteins present on all influenza strains, and potential false positive responses can be mitigated. A simple nasal swab sample diluted in water is added to the device, the sample is distributed to 4 different reagent zones, and development of the enzymatic substrate under different buffer conditions takes place on bottom of the device. Analysis can be performed by eye or through a colorimetric image analysis smartphone app.
Development of a Point-of-Care Diagnostic for Influenza Detection with Antiviral Treatment Effectiveness Indication
Video Jun 23, 2015
Dr Erik Procko has been working on engineering a "decoy" receptor for SARS-CoV-2, the virus that has caused the COVID-19 global pandemic. In the second video of this two-part installment, Dr Procko discusses his research in exploring the mutational landscape of ACE2 to further understand the interaction between the receptor and the S protein of SARS-CoV-2.WATCH NOW